Recent trends in niosome as vesicular drug delivery system

Journal of Applied Pharmaceutical Science

Volumn 2, Issue 6, 2012, Pages 20-32

  Sankhyan, Anchal ^a   Pawar, Pravin ^a  

^a CHITKARA UNIVERSITY   (India)

Author keywords

Cholesterol; Niosomes; Nonionic surfactant; Vesicular system

Indexed keywords

EID: 84875708671     PISSN: None     EISSN: 22313354     Source Type: Journal    
DOI: 10.7324/JAPS.2012.2625     Document Type: Article

References (119)

1. Abdelbary A., Essam T., Abd El-Salam R. M., AlyKassem A. A. Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin (antifungal). Drug Dev Ind Pharm. 2011; 37: 149- 508.
2. Abdelbary G., El-Gendy N. Niosome-Encapsulated Gentamicin for Ophthalmic Controlled Delivery. AAPS PharmSciTech. 2008; 9: 740- 747.
3. Abdelkader H., Ismail S., Kamal A., Alany R. G. Preparation of niosomes as an ocular delivery system for naltrexone hydrochloride: physicochemical characterization. Pharmazie. 2010; 65: 811-817.
4. Aggarwal D., Kaur I.P. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. Int J Pharm. 2005; 290: 155-159.
5. Alvi I. A., Madan J., Kaushik D., Sardana S., Pandey R.S., Ali A. Comparative study of transfersomes, liposomes, and niosomes for topical delivery of 5-fluorouracil to skin cancer cells: preparation, .characterization, in-vitro release, and cytotoxicity analysis. Anticancer Drugs. 2011; 22: 774-782.
6. Arora R., Sharma A. Release Studies of Ketoprofen Niosome Formulation. J Chem Pharm Res. 2010; 2: 79-82.
7. Arunothayanun P., Turton J. A., Uchegbu I. F., Florence A. T. Preparation and in vitro/in vivo evaluation of luteinizing hormone releasing hormone (LHRH)-loaded polyhedral and spherical/tubular niosomes. J Pharm Sci. 1999; 88 :34-38.
8. Azmin M. N., Florence A. T., Handjani-Vila R.M., Stuart J.F., Vanlerberghe G., Whittaker J. S. The effect of non-ionic surfactant vesicle (niosome) entrapment on the absorption and distribution of methotrexate in mice. J Pharm Pharmacol. 1985; 37: 237-242.
9. Azmin M. N., Florence A. T., Handjani-Vila R. M., Stuart J. F., Vanlerberghe G., Whittaker J. S. The effect of niosomes and polysorbate 80 on the metabolism and excretion of methotrexate in the mouse. J Microencapsul. 1986; 3: 95-100.
10. Baillie A. J., Coombs G. H., Dolan T.F., Laurie J. Non-ionic surfactant vesicles, niosomes, as a delivery system for the anti-leishmanial drug, sodium stibogluconate. J Pharm Pharmacol. 1986; 38: 502-505.
11. Baillie A. J., Florence A. T., Hume L. R., Muirhead G. T., Rogerson A. The preparation and properties of niosomes--non-ionic surfactant vesicles. J Pharm Pharmacol. 1985; 37: 863-868.
12. Bandyopadhyay P., Johnson M. Fatty alcohols or fatty acids as niosomal hybrid carrier: effect on vesicle size, encapsulation efficiency and in vitro dye release. Colloids Surf B Biointerfaces. 2007; 58: 68-71.
13. Barakat H. S., Darwish I. A., El-Khordagui L. K., Khalafallah N. M. Development of naftifine hydrochloride alcohol-free niosome gel. Drug Dev Ind Pharm. 2009; 35: 631-637.
14. Bayindir Z. S., Yuksel N. Characterization of niosomes prepared with various nonionic surfactants for paclitaxel oral delivery. J Pharm Sci. 2010; 99: 2049-2060.
15. Biju S. S., Talegaonkar S., Mishra P. R., Khar R. K. Vesicular systems: An overview. Indian J Pharm Sci. 2006; 68: 141-153.
16. Brewer M., Alexander J. Studies on the adjuvant activity of nonionic surfactant vesicles: adjuvant-driven IgG2a production independent of MHC control. Vaccine. 1994; 12: 613-619.
17. Carafa M., Santucci E., Lucania G. Lidocaine-loaded non-ionic surfactant vesicles characterization and in vitro permeation studies. Int J Pharm. 2002; 231: 21-32.
18. Carter K.C. et al. The therapeutic effect of sodium stibogluconate in BALB:c mice infected with Leishmania donobani is organ dependent. J Pharm Pharmacol. 1988; 40: 370-373.
19. Chauhan S., Luorence M. J. The preparation of polyoxyethylene containing non-ionic surfactant Vesicles. J Pharm Pharmacol. 1989; 41: 6.
20. Confalonieri E. O., Soraci A. L., Becaluba M., Denzoin L., Rodriguez E., Riccio B., Tapia O. The disposition of free and niosomally encapsulated Rac-flurbiprofen in dairy bovines. J Vet Pharmacol Ther. 2010; 33: 9-14.
21. Cosco D., Paolino D., Muzzalupo R., Celia C., Citraro R., Caponio D., Picci N., Fresta M. Novel PEG-coated niosomes based on bola-surfactant as drug carriers for 5-fluorouracil. Biomed Microdevices. 2009; 11: 1115-1125.
22. Dahiya N. K., Rao R., Nanda S. Preparation and characterization techniques in niosomal vesicular systems- A review. J. Pharm. Biomed. Sci. 2011; 5:1-8.
23. Desai A. R., Raghuveer I., Chitme H. R., Chandra R. Development and characterization of niosomal drug delivery of atocopherol. Int. J. Chem. Anal. Sci. 2010; 1: 146-158.
24. Dufes C., Muller J. M., Couet W., Olivier J. C., Uchegbu I. F., Schatzlein A. G. Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles. Pharm Res. 2004; 21: 101-107.
25. Dufes C., Schatzlein A. G., Tetley L., Gray A. I., Watson D. G., Olivier J. C., Couet W., Uchegbu I. F. Niosomes and Polymeric Chitosan Based Vesicles Bearing Transferrin and Glucose Ligands for Drug Targeting. Pharm Res. 2000; 17: 1250-1258.
26. El-Menshawe S. F., Hussein A. K. Formulation and evaluation of meloxicam niosomes as vesicular carriers for enhanced skin delivery. Pharm Dev Technol. 2011. (Epub ahead of print).
27. El-Ridy M. S., Abdelbary A., Nasr E. A., Khalil R. M., Mostafa D. M., El-Batal A. I., Abd El-Alim S. H. Niosomal encapsulation of the antitubercular drug, pyrazinamide. Drug Dev Ind Pharm. 2011; 37: 1110- 1118.
28. Gannu P. K., Pogaku R. Nonionic surfactant vesicular systems for effective drug delivery-an overview. Acta Pharmaceutica Sinica B. 2011; 1: 208-219.
29. Giddi H. S., Arunagirinathan M. A., Bellare J. R. Self-assembled surfactant nano-structures important in drug delivery: A review. Indian J Exp Biol. 2007; 45: 133-159.
30. Guinedi A. S., Nahed D. M., Samar M., Rania M. H. Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. Int J Pharm. 2005; 306: 71-82.
31. Gupta M., Vaidya B., Mishra N., Vyas S. P. Effect of surfactants on the characteristics of fluconazole niosomes for enhanced cutaneous delivery. Artif Cells Blood Substit Immobil Biotechnol. 2011; 39: 376- 384.
32. Handjani-Vila R. M., Ribier A., Rondot B., Vanlerberghie G. Dispersions of lamellar phases of non-ionic lipids in cosmetic products. Int J Cosmet Sci. 1979; 1: 303-314.
33. Hashim F., El-Ridy M., Nasr M., Abdallah Y. Preparation and characterization of niosomes containing ribavirin for liver targeting. Drug Deliv. 2010; 17: 282-287.
34. Hofland H. E. J. Safety aspects of non-ionic surfactant vesicles-a toxicity study related to the physicochemical characteristics of non-ionic surfactants. J Pharm Pharmacol. 1992; 44 :287-294.
35. Hong M., Zhu S., Jiang Y., Tang G., Pei Y. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J Control Release. 2009; 133: 96-102.
36. Hood E., Gonzalez M., Plaas A., Strom J., VanAuker M. Immuno-targeting of nonionic surfactant vesicles to inflammation. Int J Pharm. 2007; 339: 222-230.
37. Huang Y., Chen J., Chen X., Gao J., Liang W. PEGylated synthetic surfactant vesicles (Niosomes): novel carriers for oligonucleotides. J Mater Sci Mater Med. 2008; 19: 607-614.
38. Huang Y. Z., Gao J. Q., Chen J. L., Liang W. Q. Cationic liposomes modified with non-ionic surfactants as effective non-viral carrier for gene transfer. Colloids Surf B Biointerfaces. 2006; 49: 158-164.
39. Huang Y. Z., Han G., Wang H., Liang W. Q. Cationic niosomes as gene carriers: preparation and cellular uptake in vitro. Pharmazie. 2005; 60: 473-474.
40. Huang Y. Z., Rao Y., Chen JL., Yang V. C., Liang W. Polysorbate cationic synthetic vesicle for gene delivery. J Biomed Mater Res. 2011; 96: 513-519.
41. Hunter C. A., Dolan T. F., Coombs G. H., Baillie A. J. Vesicular systems(niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. J Pharm Pharmacol. 1988; 40: 161-165.
42. Jadon P. S., Gajbhiye V., Jadon R. S., Gajbhiye K. R., Ganesh N. Enhanced Oral Bioavailability of Griseofulvin via Niosomes. AAPS PharmSciTech. 2009; 10: 1186-1192.
43. Jain C. P., Vyas S. P. Preparation and characterization of niosomes containing rifampicin for lung targeting. J Microencapsul. 1995; 12: 401-407.
44. Jain S., Singh P., Mishra V., Vyas S. P. Mannosylated niosomes as adjuvant-carrier system for oral genetic immunization against Hepatitis B. Immunol Lett. 2005; 101: 41-49.
45. Jain S., Vyas S. P. Mannosylated niosomes as carrier adjuvant system for topical immunization. J Pharm Pharmacol. 2005; 57: 1177- 1184.
46. Jia-You F., Chi-Tzong H., Wen-Ta C., Ying-Yue W. Effect of liposomes and niosomes on skin permeation of enoxacin. Int J Pharm. 2001; 219: 61-72.
47. Junyaprasert V. B., Singhsa P., Suksiriworapong J., Chantasart D. Physicochemical properties and skin permeation of Span 60/Tween 60 niosomes of ellagic acid. Int J Pharm. 2012; 423: 303-311.
48. Karim K. M., Mandal A. S., Biswas N., Guha A., Chatterjee S., Behera M., Kuotsu K. Niosome: A future of targeted drug delivery systems. J Adv Pharm Tech Res. 2010; 1: 374-380.
49. Karki R., Mamatha G. C., Subramanya G., Udupa N. Preparation, characterization and tissue disposition of niosomes containing isoniazid. Rasayan J Chem. 2008; 1: 224-227.
50. Kaur I. P., Aggarwal D., Singh H., Kakkar S. Improved ocular absorption kinetics of timolol maleate loaded into a bioadhesive niosomal delivery system. Graefes Arch Clin Exp Ophthalmol. 2010; 248: 1467- 1472.
51. Kerr D. J., Rogerson A., Morrison G. J., Florence A. T., Kaye S. B. Antitumour activity and pharmacokinetics of niosome encapsulated adriamycin in monolayer, spheroid and xenograft. Br J Cancer. 1988; 58: 432-436.
52. Keservani R. K., Sharma A. K., Ramteke S. Novel Vesicular Approach for Topical Delivery of Baclofen via Niosomes. Lat Am J Pharm. 2010; 29: 1364-1370.
53. Khaksa G., D'Souza R., Lewis S., Udupa N. Pharmacokinetic study of niosome encapsulated insulin. Indian J Exp Biol. 2000; 38: 901- 905.
54. Khan A., Sharma P. K., Visht S., Malviya R. Niosomes as colloidal drug delivery system: A review. Journal of Chronotherapy and Drug Delivery. 2011; 2: 15-21.
55. Khandare J. N., Madhavi G., Tamhankar B. M. Niosomes novel drug delivery system. The Eastern Pharmacist. 1994; 37: 61-64.
56. Kopermsuba P., Mayena V., Warin C. Potential use of niosomes for encapsulation of nisin and EDTA and their antibacterial activity enhancement. Food Research International. 2011; 44: 605-612.
57. Lala S., Nandy A. K., Mahato S. B., Basu M. K. Delivery in vivo of 14-deoxy-11-oxoandrographolide, an antileishmanial agent, by different drug carriers. IJBB. 2003; 40: 169-174.
58. Lalaa S., Pramanickb S., Mukhopadhyayb S., Bandyopadhyayc S., Basua M. K. Harmine: Evaluation of its Antileishmanial Properties in Various Vesicular Delivery Systems. J Drug Target. 2004; 12: 165-175.
59. Maheshwari C., Pandey R. S., Chaurasiya A., Kumar A., Selvam D. T., Prasad G. B., Dixit V. K. Non-ionic surfactant vesicles mediated transcutaneous immunization against hepatitis B. Int Immunopharmacol. 2011; 11: 1516-1522.
60. Mahmoud M., Omaima A. S., Mohammed A. H., Nagia A. M. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int J Pharm. 2008; 361: 104-111.
61. Das M. K., Palei N. N. Sorbitan ester niosomes for topical delivery of rofecoxib. Indian J Exp Biol. 2011; 49: 438-445.
62. Manconi M., Sinico C., Valenti D., Lai F., Fadda A. M. Niosomes as carriers for tretinoin:III. A study into the in vitro cutaneous delivery of vesicle incorporated tretinoin. Int J Pharm. 2006; 311: 11-9.
63. Manconi M., Sinico C., Valenti D., Loy G., Fadda A. M. Niosomes as carriers for tretinoin. I. Preparation and properties. Int J Pharm. 2002; 234: 237-248.
64. Manosroi A., Jantrawut P., Akazawa H., Akihisa T., Manosroi W., Manosroi J. Transdermal absorption enhancement of gel containing elastic niosomes loaded with gallic acid from Terminalia chebula galls. Pharm Biol. 2011; 49: 553-562.
65. Manosroi A., Khanrin P., Werner R. G., Götz F., Manosroi W., Manosroi J. Entrapment enhancement of peptide drugs in niosomes. J Microencapsul. 2010; 27: 272-280.
66. Manosroi A., Khositsuntiwong N., Götz F., Werner R. G., Manosroi J. Transdermal enhancement through rat skin of luciferase plasmid DNA loaded in elastic nanovesicles. J Liposome Res. 2009; 19: 91-98.
67. Manosroi A., Lohcharoenkal W., Götz F., Werner R. G., Manosroi W., Manosroi J. Cellular uptake enhancement of Tat-GFP fusion protein loaded in elastic niosomes. J Biomed Nanotechnol. 2011;7:366- 376.
68. Manosroi J., Lohcharoenkal W., Götz F., Werner R. G., Manosroi W., Manosroi A. Transdermal absorption enhancement of nterminal tat-GFP fusion protein (TG) loaded in novel low-toxic elastic anionic niosomes. J Pharm Sci. 2010; 100: 1525-1534.
69. Manosroia A., Khanrina P., Lohcharoenkala W., Werner R. G., Götzd F., Manosroie W., Manosroia J. Transdermal absorption enhancement through rat skin of gallidermin loaded in niosomes. Int J Pharm. 2010; 392: 304-310.
70. Marianeccia C., Paolino D., Celia C., Fresta M., Carafa M., Alhaique F. Non-ionic surfactant vesicles in pulmonary glucocorticoid delivery: Characterization and interaction with human lung fibroblasts. J Control Release. 2010; 147: 127-135.
71. Mayer L. D., Bally M. B., Hope M. J., Cullis P. R. Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. Biochem Biophys Acta. 1985; 816: 294-302.
72. Medda S., Mukhopadhyay S., Basu M. K. Evaluation of the invivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms. J Antimicrob Chemother. 1999; 44: 791- 794.
73. Mehta S. K., Jindal N., Kaur G. Quantitative investigation, stability and in vitro release studies of anti-TB drugs in Triton niosomes. Colloids Surf B Biointerfaces. 2011; 87: 173-179.
74. Moser P., Marchand-Arvier M., Labrude P., Handjani-Vila R. M., Vigneron C. Hemoglobin niosomes: Preparation, functional and physico-chemical properties, and stability. Pharm Acta Helv. 1989; 64: 192-202.
75. Mujoriya R. Z., Bodla R. B. Niosomes - challenge in preparation for pharmaceutical scientist. Int J App Pharm. 2011; 3: 11-15.
76. Muller D., Foulon M., Bonnemain B., Vandamme T. F. Niosomes as carriers of radiopaque contrast agents for X-ray imaging. J Microencapsul. 2000; 17: 227-243.
77. Mura S., Pirot F., Manconi M., Falson F., Fadda A. M. Liposomes and niosomes as potential carriers for dermal delivery of minoxidil. J Drug Target. 2007; 15: 101-108.
78. Namdeo A., Jain N. K. Niosomal delivery of 5-fluorouracil. J Microencapsul. 1999; 16: 731-740.
79. Naresh R. A., Udupa N., Devi P. U. Niosomal plumbagin with reduced toxicity and improved anticancer activity in BALB/C mice. J Pharm Pharmacol. 1996; 48: 1128-1132.
80. Ning M., Guo Y., Pan H., Chen X., Gu Z. Preparation, in Vitro and in Vivo Evaluation of Liposomal/Niosomal Gel Delivery Systems for Clotrimazole. Drug Dev Ind Pharm. 2005; 31: 375-383.
81. Palozza P., Muzzalupo R., Trombino S., Valdannini A., Picci N. Solubilization and stabilization of beta-carotene in niosomes: delivery to cultured cells. Chem Phys Lipids. 2006; 139: 32-42.
82. Paolino D., Muzzalupo R., Ricciardi A., Celia C., Picci N., Fresta M. In vitro and in vivo evaluation of Bola-surfactant containing niosomes for transdermal delivery. Biomed Microdevices. 2007; 9: 421- 433.
83. Patel R., Patel K. P. Advances in novel parentral drug delivery systems. Asian J Pharm. 2010; 4: 193-199.
84. Pillai G. K., Salim M. L. Enhanced inhibition of platelet aggregation in-vitro by niosome-encapsulated indomethacin. Int J Pharm. 1999; 193: 123-127.
85. Raja R. A. N., Pillai G. K., Udupa N., Chandrashekar G. Antiinflammatory activity of niosome encapsulated diclofenac sodium in arthritic rats. Indian J Pharmacol. 1994; 26: 46-48.
86. Raja R. A. N., Udupa N., Devi P. U. Effect of macrophage activation on niosome encapsulated bleomycin in tumor bearing mice. Indian J Pharmacol. 1996; 28: 175-180.
87. Rentel C. O., Bouwstra J. A., Naisbett B., Junginger H. E. Niosomes as a novel peroral vaccine delivery system. Int J Pharm. 1999; 186: 161-167.
88. Rogerson A., Cummings J., Florence A. T. Adriamycin-loaded niosomes: drug entrapment, stability and release. J Microencapsul. 1987; 4: 321-328.
89. Rogerson A., Cummings J., Willmott N., Florence A. T. The Distribution of Doxorubicin in Mice Following Administration in Niosomes. J Pharm Pharmacol. 1988; 40: 337-342.
90. Ruckmani K., Jayakar B., Ghosal S. K. Nonionic surfactant vesicles (niosomes) of cytarabine hydrochloride for effective treatment of leukemias: encapsulation, storage, and in vitro release. Drug Dev Ind Pharm. 2000; 26: 217-222.
91. Ruckmani K., Sankar V., Sivakumar M. Tissue distribution, pharmacokinetics and stability studies of zidovudine delivered by niosomes and proniosomes. J Biomed Nanotechnol. 2010; 6: 43-51.
92. Sambathkumar R., Sekharbabu V., Perumal P., Murthy N. V., Kanagasabi R., Vijaya R., Manikander M. Development and evaluation of cefpodoxime proxetil niosomes using various sorbitan esters. Res J Pharm Biol and Chem Sci. 2011; 2: 213-219.
93. Sambhakar S., Singh B., Paliwal S. K., Mishra P. R. Niosomes as a Potential Carrier for Controlled Release of Cefuroxime Axetil. Asian J Biochem and Pharm Res. 2011; 1: 126-136.
94. Sarkar S., Mandal S., Sinha J., Mukhopadhyay S., Das N., Basu M. K. Quercetin: Critical Evaluation as an Antileishmanial Agent In Vivo in Hamsters Using Different Vesicular Delivery Modes. J Drug Target. 2002; 10: 573-578.
95. Shahiwala A., Misra A. Studies in topical application of niosomally entrapped Nimesulide. J Pharm Pharmaceut Sci. 2002; 5: 220- 225.
96. Shan W., Liu H., Shi J., Yang L., Hu N. Self-assembly of electroactive layer-by-layer films of heme proteins with anionic surfactant dihexadecyl phosphate. Biophys Chem. 2008; 134: 101-109.
97. Shatalebi M. A., Mostafavi S. A., Moghaddas A. Niosome as a drug carrier for topical delivery of N-acetyl glucosamine. Res Pharm Sci. 2010; 5: 107-117.
98. Shenoy B. D., Udupa N., Singh U. V., Kumari N. In-vitro and in-vivo evaluation of novel injectable contraceptive preparations of centchroman. Indian J Pharmacol. 1997; 29: 233-237.
99. Sihorkar V., Vyas S.P. Polysaccharide coated niosomes for oral drug delivery: formulation and in vitro stability studies. Pharmazie. 2000; 55: 107-113.
100. Singh G., Dwivedi H., Saraf S. K., Saraf S. A. Niosomal delivery of isoniazid - development and characterization. Trop J Pharm Res. 2011; 10: 203-210.
101. Sinha J., Raay B., Das N., Medda S., Garai S., Mahato S. B., Basu M. K. Bacopasaponin C: Critical Evaluation of Anti-Leishmanial Properties in Various Delivery Modes. Drug Deliv. 2002; 9: 55-62.
102. Solankia A. B., Parikh J. R., Parikh R. H., Patel M. R. Evaluation of different compositions of niosomes to optimize Aceclofenac transdermal delivery. AJPS. 2010; 5: 87-95.
103. Srinivas S., Kumar Y. A., Hemanth A., Anitha M. Preparation and Evaluation of Niosomes Containing Aceclofenac. Dig J Nanomater Bios. 2010; 5: 249-254.
104. Tabbakhian M., Tavakoli N., Jaafari M. R., Daneshamouz S. Enhancement of follicular delivery of finasteride by liposomes and niosomes 1. In vitro permeation and in vivo deposition studies using hamster flank and ear models. Int J Pharm. 2006; 323: 1-10.
105. Tamizharasi S., Dubey A., Rathi V., Rathi J. C. Development and characterization of niosomal drug delivery of gliclazide. J Young Pharm. 2009; 1: 205-209.
106. Tavano L., Alfano P., Muzzalupo R., Cindio B. Niosomes vs microemulsions: New carriers for topical delivery of Capsaicin. Colloids Surf B Biointerfaces. 2011; 87: 333-339.
107. Uchegbu I. F., Double J. A., Kelland L. R., Turton J. A., Florence A. T. The activity of doxorubicin niosomes against an ovarian cancer cell line and three in vivo mouse tumour models. J Drug Target. 1996; 3: 399-409.
108. Uchegbu I. F., Double J. A., Turton J. A., Florence A. T. Distribution, Metabolism and Tumoricidal activity of doxorubicin administered in sorbitan monostearate (Span60) Niosomes in the mouse. Pharm Res. 1995; 7: 1019-1024.
109. Uchegbu I. F., Turton J. A., Double J. A., Florence A. T. Drug distribution and pulmonary adverse effect of intraperitoneally administered doxorubicin niosomes in the mouse. Biopharm Drug Dispos. 1994; 15: 691-707.
110. Udupa, N. (2004). Niosomes as drug carriers. In: N. K. Jain. Controlled and Novel Drug Delivery (pp. 292-303). New Delhi: CBS Publishers & Distributors.
111. Varshosaz J., Pardakhty A., Hajhashemi V. I., Najafabadi A. R. Development and physical characterization of sorbitan monoester niosomes for insulin oral delivery. Drug Deliv. 2003; 10: 251-262.
112. Vyas SP and Khar RK. Targeted and Controlled Drug Delivery Novel Carrier Systems. CBS Publishers and Distributors, New Delhi (2011) 249 -279.
113. Williams D., Mullen A. B., Baillie A. J., Carter K. C. Comparison of the efficacy of free and non-ionic-surfactant vesicular formulations of paromomycin in a murine model of visceral leishmaniasis. J Pharm Pharmacol. 1998; 50: 1351-1356.
114. Yang C. Y., Yin C., Zhou Y. Y., Dai Z. X. Electrochemical properties of niosomes modified Au electrode and DNA recognition. Colloids Surf B Biointerfaces. 2008; 67: 179-182.
115. Yasin M. N., Hussain S., Malik F., Hameed A., Sultan T., Qureshi F., Riaz H., Perveen G., Wajid A. Preparation and characterization of chloramphenicol niosomes and comparison with chloramphenicol eye drops (0.5%w/v) in experimental conjunctivitis in albino rabbits. Pak J Pharm Sci. 2012; 25: 117-121.
116. Yoshida H. et al. Niosomes for oral delivery of peptide drugs. J Control Release. 1992; 21: 145-153.
117. Zhang M., Kataoka K. Nano-structured composites based on calcium phosphate for cellular delivery of therapeutic and diagnostic agents. Nanotoday. 2009; 4: 508-517.
118. Zidan A. S., Mokhtar M. Multivariate optimization of formulation variables influencing flurbiprofen proniosomes characteristics. J Pharm Sci. 2011; 100: 2212-2221.
119. Zidana A. S., Rahmana Z., Khan M. A. Product and process understanding of a novel pediatric anti-HIV tenofovir niosomes with a high-pressure homogenizer. Eur J Pharm Sci. 2011; 44: 93-102.